Zamaporvint clinical trials
Also written RXC004.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses zamaporvint has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Redx Pharma Ltd (3)
Studies
Open first, then newest update. How each study uses zamaporvint has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedPhase 2Redx Pharma LtdNCT04907539Written as RXC004Report a problem
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)CompletedPhase 2Redx Pharma LtdNCT04907851Written as RXC004Report a problem
- Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesCompletedPhase 1Redx Pharma LtdNCT03447470Written as RXC004Report a problem
Tested with established drugs · 3 — they are given beside it
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedPhase 2Redx Pharma LtdNCT04907539Written as RXC004Report a problem
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)CompletedPhase 2Redx Pharma LtdNCT04907851Written as RXC004Report a problem
- Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesCompletedPhase 1Redx Pharma LtdNCT03447470Written as RXC004Report a problem
Codes
What other systems call zamaporvint · ClinicalTrials.gg INT017245
- UNII (FDA) M56M7CHN8EZAMAPORVINTOne source FDA
- NCI Thesaurus C156701ZamaporvintOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M56M7CHN8E | ZAMAPORVINT | One source FDA |
| NCI Thesaurus | C156701 | Zamaporvint | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.